Methylation biomarkers for early cancer detection and diagnosis: Current and future perspectives

Joe Ibrahim; Marc Peeters; Guy Van Camp; Ken Op de Beeck

doi:10.1016/j.ejca.2022.10.015

journal article Jan 01, 2023

Methylation biomarkers for early cancer detection and diagnosis: Current and future perspectives

Joe Ibrahim

Marc Peeters

Guy Van Camp

Ken Op de Beeck

European Journal of Cancer Vol. 178 pp. 91-113 · Elsevier BV

View at Publisher Save 10.1016/j.ejca.2022.10.015

Topics

No keywords indexed for this article. Browse by subject →

References

200

[1]

World Health Organization n.d. https://www.who.int/ [accessed 19.02.19].

[2]

Globocan (2020)

[3]

Ramón "Clinical implications of intratumor heterogeneity: challenges and opportunities" J Mol Med (2020) 10.1007/s00109-020-01874-2

[4]

Meacham "Tumour heterogeneity and cancer cell plasticity" Nature (2013) 10.1038/nature12624

[5]

Fisher "Cancer heterogeneity: implications for targeted therapeutics" Br J Cancer (2013) 10.1038/bjc.2012.581

[6]

Hallmarks of Cancer: The Next Generation

Douglas Hanahan, Robert A. Weinberg

Cell 2011 10.1016/j.cell.2011.02.013

[7]

Jones "The fundamental role of epigenetic events in cancer" Nat Rev Genet (2002) 10.1038/nrg816

[8]

Crosby "A roadmap for the early detection and diagnosis of cancer" Lancet Oncol (2020) 10.1016/s1470-2045(20)30593-3

[9]

Atkinson "Biomarkers and surrogate endpoints: preferred definitions and conceptual framework" Clin Pharmacol Ther (2001) 10.1067/mcp.2001.113989

[10]

Henry "Cancer biomarkers" Mol Oncol (2012) 10.1016/j.molonc.2012.01.010

[11]

Marrugo-Ramírez "Blood-based cancer biomarkers in liquid biopsy: a promising non-invasive alternative to tissue biopsy" Int J Mol Sci (2018) 10.3390/ijms19102877

[12]

Kilgour "Liquid biopsy-based biomarkers of treatment response and resistance" Cancer Cell (2020) 10.1016/j.ccell.2020.03.012

[13]

McDonald "Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer" Sci Transl Med (2019) 10.1126/scitranslmed.aax7392

[14]

Luo "Circulating tumor DNA methylation profiles enable early diagnosis, prognosis prediction, and screening for colorectal cancer" Sci Transl Med (2020) 10.1126/scitranslmed.aax7533

[15]

Osumi "Circulating tumor DNA as a novel biomarker optimizing chemotherapy for colorectal cancer" Cancers (2020) 10.3390/cancers12061566

[16]

Direct detection of early-stage cancers using circulating tumor DNA

Jillian Phallen, Mark Sausen, Vilmos Adleff et al.

Science Translational Medicine 2017 10.1126/scitranslmed.aan2415

[17]

Uesato "Evaluation of circulating tumor DNA as a biomarker in pancreatic cancer with liver metastasis" PLoS One (2020) 10.1371/journal.pone.0235623

[18]

Duffy "Circulating tumour DNA as a cancer biomarker" Ann Clin Biochem (2019) 10.1177/0004563218798401

[19]

Schübeler "Function and information content of DNA methylation" Nature (2015) 10.1038/nature14192

[20]

Nakagawa "Whole genome sequencing analysis for cancer genomics and precision medicine" Cancer Sci (2018) 10.1111/cas.13505

[21]

Epigenetic modulators, modifiers and mediators in cancer aetiology and progression

Andrew P. Feinberg, Michael A. Koldobskiy, Anita Göndör

Nature Reviews Genetics 2016 10.1038/nrg.2016.13

[22]

Kondo "Epigenetic cross-talk between DNA methylation and histone modifications in human cancers" Yonsei Med J (2009) 10.3349/ymj.2009.50.4.455

[23]

Alvarez "Widespread hypomethylation occurs early and synergizes with gene amplification during esophageal carcinogenesis" PLoS Genet (2011) 10.1371/annotation/8dcded85-a924-40f4-a7ea-56961b87447f

[24]

Yong "Profiling genome-wide DNA methylation" Epigenet Chromatin (2016) 10.1186/s13072-016-0075-3

[25]

Kulis "DNA methylation and cancer" Adv Genet (2010) 10.1016/b978-0-12-380866-0.60002-2

[26]

Baylin "Epigenetic determinants of cancer" Cold Spring Harb Perspect Biol (2016) 10.1101/cshperspect.a019505

[27]

Kanwal "Epigenetic modifications in cancer" Clin Genet (2012) 10.1111/j.1399-0004.2011.01809.x

[28]

Gaudet "Induction of tumors in mice by genomic hypomethylation" Science (2003) 10.1126/science.1083558

[29]

DNA methylation in cancer: too much, but also too little

Melanie Ehrlich

Oncogene 2002 10.1038/sj.onc.1205651

[30]

Ehrlich "DNA hypomethylation in cancer cells" Epigenomics (2009) 10.2217/epi.09.33

[31]

Zhong "Aberrant promoter methylation profiles and association with survival in patients with hepatocellular carcinoma" OncoTargets Ther (2017) 10.2147/ott.s128058

[32]

Upchurch "Aberrant promoter hypomethylation in CLL: does it matter for disease development?" Front Oncol (2016) 10.3389/fonc.2016.00182

[33]

Wu "Aberrant promoter methylation of cancer-relatedgenes in human breast cancer" Oncol Lett (2016) 10.3892/ol.2016.5351

[34]

Esteller "Epigenetic gene silencing in cancer: the DNA hypermethylome" Hum Mol Genet (2007) 10.1093/hmg/ddm018

[35]

Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation

Maria E. Figueroa, Omar Abdel-Wahab, Chao Lu et al.

Cancer Cell 2010 10.1016/j.ccr.2010.11.015

[36]

Rasmussen "Loss of TET2 in hematopoietic cells leads to DNA hypermethylation of active enhancers and induction of leukemogenesis" Genes Dev (2015) 10.1101/gad.260174.115

[37]

Dalgliesh "Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes" Nature (2010) 10.1038/nature08672

[38]

Roberti "Epigenetics in cancer therapy and nanomedicine" Clin Epigenetics (2019) 10.1186/s13148-019-0675-4

[39]

Hoadley "Cell-of-Origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer" Cell (2018) 10.1016/j.cell.2018.03.022

[40]

Zhang "Pan-cancer analysis of frequent DNA co-methylation patterns reveals consistent epigenetic landscape changes in multiple cancers" BMC Genom (2017)

[41]

Mikeska "DNA methylation biomarkers: cancer and beyond" Genes (2014) 10.3390/genes5030821

[42]

Leygo "DNA methylation as a noninvasive epigenetic biomarker for the detection of cancer" Dis Markers (2017) 10.1155/2017/3726595

[43]

Locke "DNA methylation cancer biomarkers: translation to the clinic" Front Genet (2019) 10.3389/fgene.2019.01150

[44]

Woodson "The usefulness of the detection of GSTP1 methylation in urine as a biomarker in the diagnosis of prostate cancer" J Urol (2008) 10.1016/j.juro.2007.09.073

[45]

Daniunaite "Frequent methylation of RASSF1 and RARB in urine sediments from patients with early stage prostate cancer" Medicina (2011) 10.3390/medicina47030020

[46]

Jatkoe "A urine-based methylation signature for risk stratification within low-risk prostate cancer" Br J Cancer (2015) 10.1038/bjc.2015.7

[47]

Mahon "Methylated Glutathione S-transferase 1 (mGSTP1) is a potential plasma free DNA epigenetic marker of prognosis and response to chemotherapy in castrate-resistant prostate cancer" Br J Cancer (2014) 10.1038/bjc.2014.463

[48]

Brait "Promoter methylation of MCAM, ERa and ERβ in serum of early stage prostate cancer patients" Oncotarget (2017) 10.18632/oncotarget.14873

[49]

Wang "Aberrant promoter methylation of the cadherin 13 gene in serum and its relationship with clinicopathological features of prostate cancer" J Int Med Res (2014) 10.1177/0300060514540631

[50]

Deng "Prognostic value of protocadherin10 (PCDH10) methylation in serum of prostate cancer patients" Med Sci Monit (2016) 10.12659/msm.897179

Showing 50 of 200 references

Cited By

90

SFMBT2 hypermethylation promotes colorectal cancer progression and is a potential noninvasive biomarker for advanced CRC

Wei Wang, Ling Yu · 2026

iScience

Evaluation and integration of cell-free DNA signatures for detection of lung cancer

Ruyue Xue, Xiaomin Li · 2024

Cancer Letters

Metrics

90

Citations

200

References

Details

Published: Jan 01, 2023
Vol/Issue: 178
Pages: 91-113
License: View

Authors

Center for Oncological Research (CORE), University of Antwerp, 2610 Wilrijk, Belgium; Department of Oncology, Antwerp University Hospital, 2650 Edegem, Belgium

G

Guy Van Camp

Onze Lieve Vrouwziekenhuis Hospital

K

Ken Op de Beeck

Cite This Article

Joe Ibrahim, Marc Peeters, Guy Van Camp, et al. (2023). Methylation biomarkers for early cancer detection and diagnosis: Current and future perspectives. European Journal of Cancer, 178, 91-113. https://doi.org/10.1016/j.ejca.2022.10.015

Methylation biomarkers for early cancer detection and diagnosis: Current and future perspectives

You May Also Like